Bøker i Developments in Cardiovascular-serien

One Introduction.- One Anatomy of the Heart and of the Large Vessels.- Internal anatomy.- A. The ventricles.- B. The atria.- C. The coronary vessels.- D. The pericardium.- E. The anatomy of the large vessels.- 1. The main pulmonary artery.- 2. The aorta.- 3. The pulmonary veins.- 4. The vena cava system.- Two Principles of Cardiac Mr Imaging.- I: Basic physical principles of nuclear magnetic resonance.- I-1. Nuclei - Magnetic dipolar moment - Small magnet.- I-2. Spin and gyromagnetic ratio.- I-3. Static magnetic fields.- I-4. Precession - Resonant frequency - Longitudinal and transverse components.- I-5. Energy states and net magnetization vector.- I-6. Electromagnetic radiations - Resonance conditions.- I-7. Radiofrequency pulses.- I-8. Relaxation mechanisms - Relaxation times.- I-9. Detection of the NMR resonance signal - FID.- I-10. NMR Spectrum - Fourier transform - Chemical shift.- I-11. Experimental T2 times.- II: Advances imaging topics.- II-1. Spin-echo (SE) pulse sequence - Echo time (TE) and repetition time (TR) - Weightings.- II-2. Image contrast - Contrast weighting.- II-3. Image reconstruction.- II-4. Acquisition times - Scan time.- III: Special topics.- III-1. Fast imaging methods - Gradient echoes sequences.- III-2. Ultra fast imaging - The close future.- III-3. Flow phenomena.- III-4. Image quality.- III-5. Artefacts.- IV: References.- IV-1. Textbooks.- IV-2. Books chapters.- IV-3. Review articles.- Two Cardiac MR Imaging.- One MRI Slices of the Heart.- Transverse slices 1-13.- Sagittal slices 1-10.- Coronal slices 1-7.- LAO equivalent slices 1-10.- RAO equivalent slices 1-6.- Two Dynamic and Functional Studies.- Long axis views.- Short axis views.- Double angulation views.- End systole and end diastole.- Comprehensive Bibliography.- 1. Textbooks.- 2. Book chapters.- 3. Review articles.- 4. Technical considerations.- 5. Normal anatomy and MR-imaging planes of the heart.- 6. Ventricular function.- 7. Congenital heart disease.- 8. Valvular heart diseases.- 9. Chest, mediastinum and pulmonary hila.- 10. Myocardial ischemia and infarction.- 11. Cardiomyopathies.- 12. Contrast agents.- 13. Various heart diseases.- 14. Cardiac and paracardiac masses.- 15. Pericardium.- 16. Thoracic great vessels.- 17. Coronary arteries and grafts.- 18. Cardiac transplantation.- Anatomical Index.

Bound and Referential Pronouns.- Logical Form and Barriers in Navajo.- Towards a Modular Theory of Coreference.- Head Government in LF-Representations.- Logical Structure in Syntactic Structure: The Case of Hungarian.- In Defense of the Correspondence Hypothesis: Island Effects and Parasitic Constructions in Logical Form.- Construing WH.- Two Properties of Clitics in Clitic-Doubled Constructions.- LF Movement in Iraqi Arabic.- List of Contributors.

1. From hemodynamic principles to clinical management.- 2. The clinical use and accuracy of echo-Doppler techniques for assessing severity of disease in valvular stenotic lesions.- 3. Proper timing of valve replacement in aortic stenosis.- 4. Optimal timing of surgery for volume overload hypertrophy in mitral and aortic regurgitation.- 5. Acute effects of myocardial ischemia on left ventricular function: How to differentiate myocardial infarction, stunned myocardium, and hibernating myocardium.- 6. Effects of coronary reperfusion on left ventricular function and survival: Some remaining problems.- 7. Effects of revascularization on left ventricular function in the stunned and hibernating myocardium.- 8. Heart failure: Newer concepts and origin of symptoms.- 9. Guidelines for the evaluation of treatment in congestive heart failure.- 10. Management of patients with hypertrophic cardiomyopathy.- 11. Antiarrhytmic therapy in heart failure.- 12. Non-invasive evaluation of cardiomyopathies.- 13. Can ultrasound reliably predict acute rejection in heart transplant recipients?.- 14. Cardiac transplantation.

1. The controlled clinical trial - a model for the intricate relationships between clinical medicine and drug research.- 1.1. Introduction.- 1.2. The evolution of the controlled clinical trial (CCT).- 1.3 The implementation of the controlled clinical trial in drug research.- 1.4. Criticism of the classical view of the controlled clinical trial.- 1.5. Conclusions.- 2. The architecture of drug discovery.- 2.1. Introduction.- 1. The discovery process.- 2.2. Current views of drug discovery.- 2.2.1. Basic concepts in drug discovery.- 2.2.2. Basic epistemologies in drug discovery.- 2.3. Scientific discovery from the viewpoint of cognitive science.- 2.4. The drug discovery process revisited.- 2. The representation of knowledge about drugs and diseases.- 2.5. An epistemological analysis of the concept of drug and disease profiles.- 2.5.1. Introduction.- 2.5.2. The concept of drug profile.- 2.5.2.1..The classification of drugs.- 2.5.2.2. Incursion of drug profiles into disease profiles.- 2.5.2.3. The nature of drug characteristics.- 2.5.3. The concept of disease profile.- 2.5.3.1. Disease profiles as pigeon holes of medical knowledge.- 2.5.3.2. The fundamental basis of taxonomy in medicine.- 2.5.3.3. Convergent and divergent forces in clinical taxonomy.- 2.5.3.4. The translation of everyday medical language into the structure of profiles.- 2.5.4. Conclusions.- 3. A set-theoretical model of drug discovery.- 2.6. A definition of the concept of profile in terms of set theory.- 2.6.1. Introduction.- 2.6.2. The first aspect of a profile: membership.- 2.6.3. The second aspect of the concept of profile: values of the disease characteristics.- 2.6.4. The third aspect of the concept of profile: ranking order of characteristics.- 2.6.5. Conclusions.- 2.7. The drug discovery process - a set-theoretical model.- 2.7.1. Introduction.- 2.7.2. A naive definition.- 2.7.3. First adjustment of the naive defenition: structural and functional characteristics of drugs.- 2.7.4. Second adjustment of the naive defenition: disease characteristics.- 2.7.5. The improvement of toxic effects of drugs: positive and negative aspects and their judgment.- 2.7.6. Conclusions.- 3.Experimental and therapeutic profiling in drug innovation: the early history of the beta blockers.- 3.1. Introduction.- 3.2. Historical overview of the development of the beta blockers.- 3.3. From Dale to Ahlquist: a new methodology in pharmacology.- 3.4. Change in the concepts of agonist and antagonist.- 3.5. Experimental and therapeutic profiling in drug innovation.- 3.5.1. Cardiac arrhythmias.- 3.5.2. Angina pectoris.- 3.6. Conclusions.- 4. Industrial research and beta blockade.- 4.1. Introduction.- 4.2. Beta blocker research at Imperial Chemical Industries (ICI).- 4.2.1. The early phase.- 4.2.2. The birth of pronethalol.- 4.2.3. The demise of pronethalol.- 4.2.4. The development of propranolol.- 4.2.4.1. A "clean" drug.- 4.2.4.2. The rapid expansion of a successful drug.- 4.2.4.3. Endangered drug.- 4.2.5. The development of practolol.- 4.2.5.1. Practolol: a tool in industrial research.- 4.2.5.2. Selectivity in industrial and academic research.- 4.2.5.3. The therapeutic interest.- 4.3. The beta blocker project of Eli Lilly & Co..- 4.4. The beta blocker project of Mead Johnson.- 4.5. The beta blocker project of AB Hässle.- 4.5.1. The early phase.- 4.5.2. Intrinsic sympathomimetic activity of alprenolol.- 4.5.3. The profiling of alprenolol.- 4.5.4. Selective beta blockade.- 4.6. The beta blocker project at CIBA.- 4.7. Conclusions.- 5. Verapamil: dying drug or sleeping beauty?.- 5.1 Introduction.- 5.2 The early history of verapamil.- 5.3 Verapamil: a coronary vasodilator?.- 5.4 Verapamil: a beta blocker?.- 5.5. Verapamil: a calcium antagonist! - The elucidation of verapamil's mechanism of action by Fleckenstein.- 5.6. Citation analysis of the concept of calcium antagonism elaborated by Fleckenstein.- 5.7. The application of the theory of drug and disease profiles.- 5.7.1. Changing views on the

One: Pathophysiological considerations.- 1. The cell biology of atherosclerosis.- 2. The pathology of atherosclerosis.- Two: Occult carotid and cerebrovascular disease.- 3. The natural history of asymptomatic carotid artery disease.- 4. Techniques of screening, diagnosis and assessment of occult carotid and cerebrovascular disease.- 5. The diagnosis and management of occult atherosclerotic disease of the extra-cranial carotid artery.- Three: Occult coronary artery disease.- 6. Risk factors and epidemiology in the pathogenesis and clinical progress of occult coronary artery disease.- 7. ECG and stress testing in the diagnosis of occult atherosclerotic disease of the coronary arteries.- 8. Use of Holier monitoring in occult coronary artery disease.- 9. Radionuclide techniques in the diagnosis and assessment of occult coronary artery disease.- 10. Echocardiography in the diagnosis and assessment of occult coronary artery disease.- 11. Doppler ultrasound in the diagnosis and assessment of occult coronary artery disease.- 12. Prognosis and management of occult coronary artery disease.- 13. Occult myocardial infarction.- Four: Occult atherosclerotic disease of the aorta and arteries of the lower limbs.- 14. Epidemiology of occult atherosclerosis in the lower limbs.- 15. Occult aortic aneurysm.- 16. Occult atherosclerotic disease of arteries of the lower limb - incidence, pathophysiology, diagnosis and assessment.- 17. The detection of occult peripheral arterial disease using the one-minute exercise test.- 18. The management of occult atherosclerosis in arteries of the lower limbs.- Five: Occult atherosderotic disease of the renal and mesenteric arteries.- 19. Occult atherosclerotic involvement of the renal vasculature-pathophysiology, clinical manifestations and investigations contributing to management.- 20. Investigations of mesenteric and renal arteriosclerotic disease.- Six: New techniques, combined lesions and prevention.- 21. Use of DNA technology in the diagnosis of occult atherosclerotic disease.- 22. Occult cardiovascular atherosderotic disease in the diabetic.- 23. Who should be investigated for occult atherosderotic disease?.- 24. Prevention of occult atherosderotic disease.

1. Platelet activation and aggregation: rationale for combining antithrombotic drugs.- 2. Role of nitric oxide in endothelial cell - platelet interactions.- 3. Platelets and megakaryocytes in vascular disease.- 4. Thrombosis in relation to atherosclerosis.- 5. Pharmacological inhibition of the ADP-GP IIb/IIIa-fibrinogen pathway of platelet aggregation.- 6. Calcium fluxes in platelets and endothelial cells, mechanisms and functional significance.- 7. Inhibition of platelet function by cyclic nucleotides and cyclic nucleotide-dependent protein kinases.- 8. Pharmacological modification of platelet-derived cyclooxygenase product formation and its consequences for platelet-vessel wall interactions.- 9. Antithrombotics and the lipoxygenase pathway.- 10. Pathological expressions of platelet-vessel wall interactions: implications of serotonin.- 11. The involvement of PAF in thrombotic events.- 12. Prostaglandins and -analogs in the treatment of platelet-vessel wall interaction.- 13. Adjuvant agents to enhance and sustain reperfusion with t-PA: studies in experimental dog models.- 14. Effect of dietary marine lipids on (anti-)thrombotic mechanisms.

In recent years there have been major advances in the fields of cardiovascular nuclear medicine and cardiac magnetic resonance imaging. In nuclear cardiology more adequate tomographic systems have been designed for routine cardiac use, as well as new or improved quantitative analytic software packages both for planar and tomographic studies implemented on modern state-of-the-art workstations. In addition, artificial intelligence techniques are being applied to these images in attempts to interpret the nuclear studies in a more objective and reproducible manner. Various new radiotracers have been developed, such as antimyosin, labeled isonitriles, metabolic compounds, etc. Furthermore, alternative stress testing with dipyridamole and dobutamine has received much attention in clinical cardiac practice. Magnetic resonance imaging is a relative newcomer in cardiology and has already shown its merits, not only for anatomical information but increasingly for the functional aspects of cardiac performance. This book covers almost every aspect of quantitative cardiovascular nuclear medicine and magnetic resonance imaging. It will assist the nuclear medicine physician, the radiologist, the physicist/image processing specialist and the clinical cardiologist in understanding the nuclear medicine techniques used in cardiovascular medicine, and in increasing our knowledge of cardiac magnetic resonance imaging.